Get the Stockscreener App
1.06
7.83%
-0.09
Fibrobiologics Inc stock is traded at $1.06, with a volume of 180.70K.
It is down -7.83% in the last 24 hours and up +24.47% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.15
Open:
$1.17
24h Volume:
180.70K
Relative Volume:
1.18
Market Cap:
$7.06M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.1433
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
+8.58%
1M Performance:
+24.47%
6M Performance:
-78.88%
1Y Performance:
-90.99%
1-Day Range:
$1.02
$1.17
1-Week Range:
$0.95
$1.2792
52-Week Range:
$0.6201
$12.80
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.06 | 7.39M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
Fibrobiologics Inc (FBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fibrobiologics Inc (FBLG) Stock News Today - TradingKey
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - Morningstar
FibroBiologics patent covers Sox9 turning fibroblasts into cartilage cells - Stock Titan
H.C. Wainwright cuts FibroBiologics price target to $6 on model adjustments - Investing.com
FibroBiologics Q2 EPS beats estimates as losses narrow 72.5% - scanx.trade
FibroBiologics, Inc. Revenue Breakdown – NASDAQ:FBLG - TradingView
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets - tradingview.com
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - PR Newswire
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
FibroBiologics, Inc. 2Q 2026: Net loss $(4.12M), EPS $(0.66) — 10-Q Summary - TradingView
FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form DEF 14A FIBROBIOLOGICS For: 31 July By Investing.com - Investing.com Nigeria
FBLG Q2'26 Earnings: EPS estimate is (0.93) USD - TradingView
Fibrobiologics Inc (FBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fibrobiologics Inc (FBLG) Valuation: PE, PB & Fair Value Analysis - TradingKey
FBLG|Fibrobiologics Inc|Price:0.681|Chg%:-0.031 - TradingKey
Fibrobiologics Inc (FBLG) Institutional Confidence - TradingKey
Fibrobiologics Inc (FBLG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fibrobiologics Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Fibrobiologics Inc (FBLG) Balance Sheet - TradingKey
FBLG|Fibrobiologics Inc|Price:0.712|Chg%:-0.024 - TradingKey
FibroBiologics Market Sentiment - Benzinga España
Fibrobiologics Inc (FBLG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fibrobiologics Inc (FBLG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fibrobiologics Inc (FBLG) Earnings Date & Reports & Earnings News - TradingKey
FBLG|Fibrobiologics Inc|Price:1.020|Chg%:+0.152 - TradingKey
TradingKey - TradingKey
FibroBiologics Faces Nasdaq Delisting, Appeals Planned - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics (NASDAQ: FBLG) appeals Nasdaq move to delist its shares - Stock Titan
FibroBiologics (FBLG) Q4 2025 earnings summary - Quartr
FibroBiologics (FBLG) Registration filing Summary - Quartr
FibroBiologics (FBLG) Proxy filing Summary - Quartr
FibroBiologics (FBLG) AGM 2026 Summary - Quartr
FBLG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
FibroBiologics Inc. (FBLG) Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineCore Business Growth - dars.gov.et
Form PRE 14A FIBROBIOLOGICS For: 17 July By Investing.com - Investing.com Nigeria
FibroBiologics (NASDAQ: FBLG) puts large warrant share issuance to a stockholder vote - Stock Titan
FibroBiologics, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
FibroBiologics (Nasdaq: FBLG) files to register 12.53M warrant shares - Stock Titan
FibroBiologics director Kathleen Hallisey Rubins files initial beneficial ownership statement - Bitget
FibroBiologics Inc. (FBLG) Q1 2026 Earnings: Pre-Revenue Biotech Reports Slight EPS Miss as Stock Declines - dars.gov.et
FBLG Q1 2026 Earnings: EPS Slightly Misses Estimates as Pre-Revenue Biotech Continues R&D FocusNon-GAAP Earnings - dars.gov.et
Daily Brief Health Care: Centene Corp, FibroBiologics, Molina Healthcare, Solvonis Therapeutics and more - Smartkarma
Daily Brief United States: Apple, BlackRock, Sunrun Inc, Crude Oil, Culp Inc, Cna Financial, FibroBiologics, F&G Annuities & Life , Getty Images Holdings , Cincinnati Financial and more - Smartkarma
FibroBiologics Appoints NASA Scientist Kate Rubins to Board - The Globe and Mail
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):